Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE9A | O76083 | 3/20 | 0.36 |
| ▸ | PDE1A | P54750 | 3/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6366963 | 0.87 | MEN1 (0.37) | MEN1KMT2APDE9APDE1APDE1B | |
| SCHEMBL6368296 | 0.85 | MEN1 (0.52) | MEN1KMT2APDE9APDE1APDE1B | |
| SCHEMBL6366714 | 0.84 | PDE9A (0.41) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6366750 | 0.82 | AR (0.43) | MEN1KMT2APDE9APDE1APDE1B | |
| SCHEMBL6366229 | 0.80 | TSHR (0.46) | MEN1KMT2APDE9APDE1APDE1B | |
| SCHEMBL6365519 | 0.80 | LMNA (0.43) | MEN1KMT2APDE9APDE1APDE1B | |
| SCHEMBL6373774 | 0.80 | AR (0.46) | MEN1KMT2APDE9APDE1APDE1B | |
| SCHEMBL6365862 | 0.79 | HTT (0.46) | MEN1KMT2APDE9APDE1APDE1B | |
| SCHEMBL6365848 | 0.79 | LMNA (0.49) | MEN1KMT2APDE9APDE1APDE1B | |
| SCHEMBL6366940 | 0.78 | AR (0.48) | MEN1KMT2APDE9APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | MEN1 1265/4885KMT2A 2168/4885PDE9A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.